|
US6908744B1
(en)
*
|
2000-03-14 |
2005-06-21 |
Regeneron Pharmaceuticals, Inc. |
Methods of stimulating cartilage formation
|
|
DK1311661T3
(da)
*
|
2000-08-14 |
2012-11-26 |
Us Gov Health & Human Serv |
Forøget homolog rekombination medieret ved lambda-rekombinationsproteiner
|
|
US6586251B2
(en)
*
|
2000-10-31 |
2003-07-01 |
Regeneron Pharmaceuticals, Inc. |
Methods of modifying eukaryotic cells
|
|
US6596541B2
(en)
|
2000-10-31 |
2003-07-22 |
Regeneron Pharmaceuticals, Inc. |
Methods of modifying eukaryotic cells
|
|
US20050144655A1
(en)
|
2000-10-31 |
2005-06-30 |
Economides Aris N. |
Methods of modifying eukaryotic cells
|
|
GB0110029D0
(en)
|
2001-04-24 |
2001-06-13 |
Grosveld Frank |
Transgenic animal
|
|
CA2684022C
(en)
|
2002-05-17 |
2014-09-23 |
Mount Sinai School Of Medicine Of New York University |
Mesoderm and definitive endoderm cell populations
|
|
CN105884893A
(zh)
|
2002-07-18 |
2016-08-24 |
莫鲁斯有限公司 |
抗体混合物的重组生产
|
|
USRE47770E1
(en)
|
2002-07-18 |
2019-12-17 |
Merus N.V. |
Recombinant production of mixtures of antibodies
|
|
EP1539946A4
(en)
*
|
2002-09-09 |
2006-03-15 |
California Inst Of Techn |
METHOD AND COMPOSITIONS FOR PRODUCING HUMANIZED MICE
|
|
WO2004067725A2
(en)
*
|
2003-01-30 |
2004-08-12 |
Regeneron Pharmaceuticals, Inc. |
Methods of identifying modulators of nmur2-mediated activity
|
|
EP2395017A3
(en)
|
2003-05-30 |
2012-12-19 |
Merus B.V. |
Design and use of paired variable regions of specific binding molecules
|
|
US20100069614A1
(en)
|
2008-06-27 |
2010-03-18 |
Merus B.V. |
Antibody producing non-human mammals
|
|
PL1802193T3
(pl)
|
2004-10-19 |
2014-09-30 |
Regeneron Pharma |
Sposób wytwarzania myszy homozygotycznej pod względem modyfikacji genetycznej
|
|
US20060117396A1
(en)
*
|
2004-11-30 |
2006-06-01 |
Murphy Andrew J |
Assay methods for identifying modulators of OPSDL3 and transgenic knockouts
|
|
JP5721951B2
(ja)
|
2007-03-22 |
2015-05-20 |
バイオジェン アイデック マサチューセッツ インコーポレイテッド |
抗体、抗体誘導体、および抗体断片を含む、ｃｄ１５４に特異的に結合する結合タンパク質ならびにその使用
|
|
SI2602323T1
(en)
|
2007-06-01 |
2018-05-31 |
Open Monoclonal Technology, Inc. |
Compositions and procedures for inhibiting endogenous immunoglobin gene and the formation of transgenic human idiopathic antibodies
|
|
US20110119779A1
(en)
*
|
2007-12-10 |
2011-05-19 |
Aliva Biopharmaceuticals, Inc. |
Methods for sequential replacement of targeted region by homologous recombination
|
|
JP2011518555A
(ja)
*
|
2008-04-14 |
2011-06-30 |
サンガモ バイオサイエンシーズ， インコーポレイテッド |
標的組込みのための線形ドナーコンストラクト
|
|
US20090328240A1
(en)
*
|
2008-06-24 |
2009-12-31 |
Sing George L |
Genetically modified mice as predictors of immune response
|
|
DE102008002715A1
(de)
*
|
2008-06-27 |
2009-12-31 |
Evonik Röhm Gmbh |
2-Hydroxyisobuttersäure produzierende rekombinante Zelle
|
|
DK2346994T3
(da)
|
2008-09-30 |
2022-02-28 |
Ablexis Llc |
Knock-in-mus til fremstilling af kimære antistoffer
|
|
US9445581B2
(en)
|
2012-03-28 |
2016-09-20 |
Kymab Limited |
Animal models and therapeutic molecules
|
|
EP2517556B2
(en)
|
2009-07-08 |
2023-03-22 |
Kymab Limited |
Site-Specific Recombination Method, Rodents & Rodent Cells capable of Expressing Chimaeric Antibodies or Chains
|
|
DK3417701T3
(da)
|
2009-10-06 |
2022-03-14 |
Regeneron Pharma |
Genmodificerede mus og indpodning
|
|
JP5908405B2
(ja)
|
2009-10-29 |
2016-04-26 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
多機能性対立遺伝子
|
|
DK2509409T3
(en)
|
2009-12-10 |
2016-11-14 |
Regeneron Pharma |
MICE, WHICH PRODUCES HEAVY CHAIN ANTIBODIES
|
|
EP3336102A3
(en)
|
2009-12-21 |
2018-08-01 |
Regeneron Pharmaceuticals, Inc. |
Humanized fc gamma r mice
|
|
WO2011097603A1
(en)
|
2010-02-08 |
2011-08-11 |
Regeneron Pharmaceuticals, Inc. |
Common light chain mouse
|
|
US20130045492A1
(en)
|
2010-02-08 |
2013-02-21 |
Regeneron Pharmaceuticals, Inc. |
Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
|
|
US9796788B2
(en)
|
2010-02-08 |
2017-10-24 |
Regeneron Pharmaceuticals, Inc. |
Mice expressing a limited immunoglobulin light chain repertoire
|
|
US20120021409A1
(en)
|
2010-02-08 |
2012-01-26 |
Regeneron Pharmaceuticals, Inc. |
Common Light Chain Mouse
|
|
KR102004106B1
(ko)
|
2010-03-31 |
2019-07-25 |
아블렉시스, 엘엘씨 |
키메라 항체의 제조를 위한 비-인간 동물의 유전적 조작
|
|
US9242014B2
(en)
|
2010-06-15 |
2016-01-26 |
The Regents Of The University Of California |
Receptor tyrosine kinase-like orphan receptor 1 (ROR1) single chain Fv antibody fragment conjugates and methods of use thereof
|
|
SMT201900241T1
(it)
|
2010-06-22 |
2019-05-10 |
Regeneron Pharma |
Topi esprimenti una catena leggera ibrida di immunoglobulina con una regione variabile umana
|
|
US10662256B2
(en)
|
2010-07-26 |
2020-05-26 |
Trianni, Inc. |
Transgenic mammals and methods of use thereof
|
|
DK2597945T3
(da)
|
2010-07-26 |
2020-09-21 |
Trianni Inc |
Transgene dyr og fremgangsmåder til anvendelse deraf
|
|
US10793829B2
(en)
|
2010-07-26 |
2020-10-06 |
Trianni, Inc. |
Transgenic mammals and methods of use thereof
|
|
RS55495B1
(sr)
|
2010-08-02 |
2017-04-28 |
Regeneron Pharma |
Miševi koji stvaraju vezujuće proteine koji sadrže vl domene
|
|
EP2638155A1
(en)
|
2010-11-08 |
2013-09-18 |
Kymab Limited |
Cells & vertebrates for enhanced somatic hypermutation and class switch recombination
|
|
DK2663579T3
(en)
|
2011-01-14 |
2017-07-31 |
Univ California |
THERAPEUTIC ANTIBODIES AGAINST ROR-1 PROTEIN AND PROCEDURES FOR USE THEREOF
|
|
MX338971B
(es)
|
2011-02-15 |
2016-05-06 |
Inst Res Biomedicine Irb |
Ratones de m-csf humanizada.
|
|
US10920242B2
(en)
|
2011-02-25 |
2021-02-16 |
Recombinetics, Inc. |
Non-meiotic allele introgression
|
|
HRP20230526T1
(hr)
|
2011-02-25 |
2023-09-01 |
Regeneron Pharmaceuticals, Inc. |
Adam6 miševi
|
|
EP2631654B1
(en)
|
2011-05-12 |
2015-04-15 |
Regeneron Pharmaceuticals, Inc. |
Neuropeptide release assay for sodium channels
|
|
SI3865581T1
(sl)
|
2011-08-05 |
2024-12-31 |
Regeneron Pharmaceuticals, Inc. |
Miši s humanizirano univerzalno lahko verigo
|
|
JP2014531452A
(ja)
|
2011-09-19 |
2014-11-27 |
カイマブ・リミテッド |
動物、レパートリーおよび方法
|
|
CA2846319A1
(en)
|
2011-09-19 |
2013-03-28 |
Kymab Limited |
Antibodies, variable domains & chains tailored for human use
|
|
EP2761008A1
(en)
|
2011-09-26 |
2014-08-06 |
Kymab Limited |
Chimaeric surrogate light chains (slc) comprising human vpreb
|
|
SG10202010120XA
(en)
|
2011-10-17 |
2020-11-27 |
Regeneron Pharma |
Restricted immunoglobulin heavy chain mice
|
|
US9591835B2
(en)
|
2011-10-28 |
2017-03-14 |
Regeneron Pharmaceuticals, Inc. |
Genetically modified major histocompatibility complex animals
|
|
US9043996B2
(en)
|
2011-10-28 |
2015-06-02 |
Regeneron Pharmaceuticals, Inc. |
Genetically modified major histocompatibility complex animals
|
|
LT3262932T
(lt)
|
2011-10-28 |
2019-08-26 |
Regeneron Pharmaceuticals, Inc. |
Pelės su genetiškai modifikuotu pagrindiniu histosuderinamumo kompleksu
|
|
LT3590332T
(lt)
|
2011-10-28 |
2022-08-10 |
Regeneron Pharmaceuticals, Inc. |
Genetiškai modifikuotos pelės, ekspresuojančios chimerines pagrindinio audinių dermės komplekso (mhc) ii molekules
|
|
IN2014CN03890A
(cg-RX-API-DMAC7.html)
|
2011-10-28 |
2015-10-16 |
Regeneron Pharma |
|
|
GB2496375A
(en)
|
2011-10-28 |
2013-05-15 |
Kymab Ltd |
A non-human assay vertebrate comprising human antibody loci and human epitope knock-in, and uses thereof
|
|
AU2012332894A1
(en)
|
2011-10-31 |
2014-05-08 |
Merck Sharp & Dohme Corp. |
Nano-suspension process
|
|
GB201122047D0
(en)
|
2011-12-21 |
2012-02-01 |
Kymab Ltd |
Transgenic animals
|
|
US9253965B2
(en)
|
2012-03-28 |
2016-02-09 |
Kymab Limited |
Animal models and therapeutic molecules
|
|
PL2793567T3
(pl)
|
2011-12-20 |
2019-09-30 |
Regeneron Pharmaceuticals, Inc. |
Myszy z humanizowanym łańcuchem lekkim
|
|
PL3597038T3
(pl)
|
2012-02-01 |
2021-11-08 |
Regeneron Pharmaceuticals, Inc. |
Humanizowane gryzonie wykazujące ekspresję łańcuchów ciężkich zawierających domeny vl
|
|
AU2013204140B2
(en)
|
2012-03-06 |
2016-01-28 |
Regeneron Pharmaceuticals, Inc. |
Common light chain mouse
|
|
RU2644684C2
(ru)
|
2012-03-16 |
2018-02-13 |
Регенерон Фармасьютикалз, Инк. |
Антитела со встроенным в легкие цепи гистидином и генетически модифицированные отличные от человека животные для их получения
|
|
US20140013456A1
(en)
|
2012-03-16 |
2014-01-09 |
Regeneron Pharmaceuticals, Inc. |
Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
|
|
HUE045537T2
(hu)
|
2012-03-16 |
2019-12-30 |
Regeneron Pharma |
PH-érzékeny immunglobulin-szekvenciákat expresszáló rágcsálók
|
|
AU2013204581B2
(en)
|
2012-03-16 |
2015-06-25 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals expressing pH-sensitive immunoglobulin sequences
|
|
GB2502127A
(en)
|
2012-05-17 |
2013-11-20 |
Kymab Ltd |
Multivalent antibodies and in vivo methods for their production
|
|
US10251377B2
(en)
|
2012-03-28 |
2019-04-09 |
Kymab Limited |
Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
|
|
JP2015512635A
(ja)
|
2012-03-28 |
2015-04-30 |
カイマブ・リミテッド |
クラススイッチした完全ヒト抗体の発現のためのトランスジェニック非−ヒト脊椎動物
|
|
PT2847335T
(pt)
|
2012-04-25 |
2018-09-28 |
Regeneron Pharma |
Alvejamento mediado por nuclease com vetores de alvejamento grandes
|
|
CN104540383B
(zh)
|
2012-06-12 |
2017-08-29 |
瑞泽恩制药公司 |
具有受限制的免疫球蛋白重链基因座的人源化非人动物
|
|
AR091482A1
(es)
*
|
2012-06-21 |
2015-02-04 |
Recombinetics Inc |
Celulas modificadas geneticamente y metodos par su obtencion
|
|
KR102274722B1
(ko)
|
2012-08-23 |
2021-07-09 |
어젠시스 인코포레이티드 |
158p1d7 단백질에 결합하는 항체
|
|
ES2992753T3
(en)
|
2012-08-24 |
2024-12-17 |
Univ California |
Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis
|
|
CN120718856A
(zh)
|
2012-09-07 |
2025-09-30 |
再生元制药公司 |
经遗传修饰的非人动物及其使用方法
|
|
UA118090C2
(uk)
*
|
2012-09-07 |
2018-11-26 |
ДАУ АГРОСАЙЄНСІЗ ЕлЕлСі |
Спосіб інтегрування послідовності нуклеїнової кислоти, що представляє інтерес, у ген fad2 у клітині сої та специфічний для локусу fad2 білок, що зв'язується, здатний індукувати спрямований розрив
|
|
ES2748662T3
(es)
|
2012-11-05 |
2020-03-17 |
Institute For Res In Biomedicine Irb |
Roedores inmunodeficientes modificados genéticamente y métodos de uso de los mismos
|
|
EP3561050B1
(en)
|
2013-02-20 |
2021-12-08 |
Regeneron Pharmaceuticals, Inc. |
Genetic modification of rats
|
|
SMT201900429T1
(it)
|
2013-02-20 |
2019-09-09 |
Regeneron Pharma |
Topi esprimenti co-recettori umanizzati linfociti t
|
|
WO2014130690A1
(en)
*
|
2013-02-20 |
2014-08-28 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals with modified immunoglobulin heavy chain sequences
|
|
US20150342163A1
(en)
|
2013-02-22 |
2015-12-03 |
Regeneron Pharmaceuticals, Inc. |
Genetically modified major histocompatibility complex mice
|
|
EP2958937B1
(en)
|
2013-02-22 |
2018-08-15 |
Regeneron Pharmaceuticals, Inc. |
Mice expressing humanized major histocompatibility complex
|
|
JP6456350B2
(ja)
|
2013-03-11 |
2019-01-23 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
キメラ主要組織適合複合体（ｍｈｃ）クラスｉｉ分子を発現する遺伝子導入マウス
|
|
WO2014164640A1
(en)
|
2013-03-11 |
2014-10-09 |
Regeneron Pharmaceuticals, Inc. |
Transgenic mice expressing chimeric major histocompatibility complex (mhc) class i molecules
|
|
CA2903696A1
(en)
|
2013-03-13 |
2014-10-02 |
Regeneron Pharmaceuticals, Inc. |
Common light chain mouse
|
|
EP4545567A3
(en)
|
2013-03-13 |
2025-08-13 |
Regeneron Pharmaceuticals, Inc. |
Mice expressing a limited immunoglobulin light chain repertoire
|
|
US9788534B2
(en)
|
2013-03-18 |
2017-10-17 |
Kymab Limited |
Animal models and therapeutic molecules
|
|
HUE040575T2
(hu)
*
|
2013-04-16 |
2019-03-28 |
Regeneron Pharma |
A patkány genom célzott módosítása
|
|
US9783618B2
(en)
|
2013-05-01 |
2017-10-10 |
Kymab Limited |
Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
|
|
US11707056B2
(en)
|
2013-05-02 |
2023-07-25 |
Kymab Limited |
Animals, repertoires and methods
|
|
US9783593B2
(en)
|
2013-05-02 |
2017-10-10 |
Kymab Limited |
Antibodies, variable domains and chains tailored for human use
|
|
TWI646108B
(zh)
|
2013-08-01 |
2019-01-01 |
艾澤西公司 |
結合至ｃｄ３７蛋白質之抗體藥物結合物（ａｄｃ）
|
|
KR102138723B1
(ko)
|
2013-08-07 |
2020-07-29 |
리제너론 파마슈티칼스 인코포레이티드 |
Lincrna-결핍 비인간 동물
|
|
LT3046412T
(lt)
|
2013-09-18 |
2019-07-25 |
Regeneron Pharmaceuticals, Inc. |
Histidino pakeitimus lengvoje grandinėje turintys antikūnai ir genetiškai modifikuoti gyvūnai, išskyrus žmogų, išvesti jų gamybai
|
|
DK4269430T3
(da)
|
2013-09-23 |
2025-08-18 |
Regeneron Pharma |
Ikke-menneskelige dyr, der har et humaniseret signalregulerende proteingen
|
|
ES2993142T3
(en)
|
2013-10-01 |
2024-12-23 |
Kymab Ltd |
Animal models and therapeutic molecules
|
|
KR102173297B1
(ko)
|
2013-11-19 |
2020-11-03 |
리제너론 파마슈티칼스 인코포레이티드 |
인간화된 증식-유도 리간드 유전자를 가지고 있는 비-인간 동물
|
|
MY183188A
(en)
|
2013-11-19 |
2021-02-18 |
Regeneron Pharma |
Non-human animals having a humanized b-cell activating factor gene
|
|
US9546384B2
(en)
*
|
2013-12-11 |
2017-01-17 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for the targeted modification of a mouse genome
|
|
SMT201800653T1
(it)
|
2013-12-11 |
2019-01-11 |
Regeneron Pharma |
Metodi e composizioni per la modificazione indirizzata a bersaglio di un genoma
|
|
WO2015108102A1
(ja)
|
2014-01-15 |
2015-07-23 |
国立大学法人 群馬大学 |
Ａｔｐ可視化動物およびその用途
|
|
TWI681969B
(zh)
*
|
2014-01-23 |
2020-01-11 |
美商再生元醫藥公司 |
針對ｐｄ-１的人類抗體
|
|
ES2872475T3
(es)
|
2014-03-21 |
2021-11-02 |
Regeneron Pharma |
Animales no humanos que producen proteínas de unión de dominio único
|
|
WO2015143406A2
(en)
|
2014-03-21 |
2015-09-24 |
Regeneron Pharmaceuticals, Inc. |
Vl antigen binding proteins exhibiting distinct binding characteristics
|
|
EP4306648A3
(en)
|
2014-05-19 |
2024-04-17 |
Regeneron Pharmaceuticals, Inc. |
Genetically modified mice expressing human epo
|
|
US9497945B2
(en)
|
2014-05-30 |
2016-11-22 |
Regeneron Pharmaceuticals, Inc. |
Humanized dipeptidyl peptidase IV (DPP4) animals
|
|
LT3152312T
(lt)
|
2014-06-06 |
2020-04-27 |
Regeneron Pharmaceuticals, Inc. |
Tikslinio lokuso modifikavimo būdai ir kompozicijos
|
|
WO2015196051A1
(en)
|
2014-06-19 |
2015-12-23 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals having a humanized programmed cell death 1 gene
|
|
JP6336140B2
(ja)
|
2014-06-23 |
2018-06-06 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
ヌクレアーゼ媒介ｄｎａアセンブリ
|
|
EP3461885B1
(en)
|
2014-06-26 |
2021-10-20 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for targeted genetic modifications and methods of use
|
|
JP2017529841A
(ja)
|
2014-09-19 |
2017-10-12 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
キメラ抗原受容体
|
|
JP2017536811A
(ja)
|
2014-10-15 |
2017-12-14 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
多能性細胞の樹立又は維持のための方法及び組成物
|
|
HUE044907T2
(hu)
*
|
2014-11-21 |
2019-11-28 |
Regeneron Pharma |
Módszerek és készítmények célzott genetikai módosításhoz, párosított mutató RNS-ek használatával
|
|
RS63410B1
(sr)
|
2014-11-24 |
2022-08-31 |
Regeneron Pharma |
Ne-humane životinje koje eksprimiraju humanizovani cd3 kompleks
|
|
BR112017010490A2
(pt)
|
2014-12-05 |
2018-04-03 |
Regeneron Pharma |
roedor, polipeptídeo cd47, célula ou tecido de roedor isolado, célula-tronco emprionária de roedor, embrião de roedor, e, métodos de produzir um roedor, de fornecimento de um roedor, de enxerto de células humanas em um roedor, de avaliação de eficácia terapêutica de uma droga direcionada a células humanas e de avaliar as propriedades farmacocinéticas, de avaliar a toxicidade específica e inespecífica de uma droga direcionada ao cd47 humano.
|
|
LT3230320T
(lt)
|
2014-12-09 |
2021-01-11 |
Regeneron Pharmaceuticals, Inc. |
Gyvūnai, išskyrus žmogų, turintys humanizuotą diferenciacijos klasterio 274 geną
|
|
NZ732895A
(en)
*
|
2014-12-19 |
2022-05-27 |
Regeneron Pharma |
Methods and compositions for targeted genetic modification through single-step multiple targeting
|
|
UA122331C2
(uk)
|
2015-03-09 |
2020-10-26 |
Едженсіс, Інк. |
Антитіло проти flt3 та кон'югат антитіло-лікарський засіб (adc), який зв'язується з білком flt3
|
|
US10285387B2
(en)
|
2015-03-16 |
2019-05-14 |
Regeneron Pharmaceuticals, Inc. |
Non-human animal exhibiting diminished upper and lower motor neuron function and sensory perception
|
|
JP2018508224A
(ja)
|
2015-03-19 |
2018-03-29 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
抗原を結合する軽鎖可変領域を選択する非ヒト動物
|
|
DK3280257T3
(da)
|
2015-04-06 |
2023-09-04 |
Regeneron Pharma |
Humaniseret T-celle-formidlet immunrespons i ikke-humane dyr
|
|
PT3282835T
(pt)
|
2015-04-13 |
2023-07-25 |
Univ Yale |
Ratinhos knockin de sirpa-il15 humanizadas e métodos de utilização dos mesmos
|
|
JP6913030B2
(ja)
|
2015-05-18 |
2021-08-04 |
アジェンシス，インコーポレイテッド |
Ａｘｌタンパク質に結合する抗体
|
|
US10395759B2
(en)
|
2015-05-18 |
2019-08-27 |
Regeneron Pharmaceuticals, Inc. |
Methods and systems for copy number variant detection
|
|
US10787516B2
(en)
|
2015-05-18 |
2020-09-29 |
Agensys, Inc. |
Antibodies that bind to AXL proteins
|
|
ES3009538T3
(en)
|
2015-05-29 |
2025-03-27 |
Regeneron Pharma |
Rodent cells having a disruption in a c9orf72 locus
|
|
HK1255346A1
(zh)
|
2015-09-02 |
2019-08-16 |
Regeneron Pharmaceuticals, Inc. |
前列腺癌的啮齿动物模型
|
|
TWI752920B
(zh)
|
2015-10-12 |
2022-01-21 |
美商再生元醫藥公司 |
活化瘦素受體的抗原結合蛋白
|
|
LT3376857T
(lt)
*
|
2015-11-20 |
2021-06-25 |
Regeneron Pharmaceuticals, Inc. |
Gyvūnai, ne žmonės, turintys humanizuotą limfocitų aktyvavimo geną
|
|
ES2959326T3
(es)
*
|
2015-11-24 |
2024-02-23 |
Glaxosmithkline Ip Dev Ltd |
Líneas celulares estables para producción retroviral
|
|
DE102016122317A1
(de)
*
|
2015-11-24 |
2017-05-24 |
Glaxosmithkline Intellectual Property Development Limited |
Transientes transfektionsverfahren für retrovirale produktion
|
|
US10813346B2
(en)
|
2015-12-03 |
2020-10-27 |
Trianni, Inc. |
Enhanced immunoglobulin diversity
|
|
KR102482103B1
(ko)
|
2016-01-13 |
2022-12-28 |
리제너론 파마슈티칼스 인코포레이티드 |
조작된 중쇄 다양성 영역을 갖는 설치류
|
|
US20170218398A1
(en)
*
|
2016-01-30 |
2017-08-03 |
Markus Alexander Brown |
Method to selectively target cancerous cells for genetic manipulation
|
|
US11053288B2
(en)
|
2016-02-04 |
2021-07-06 |
Trianni, Inc. |
Enhanced production of immunoglobulins
|
|
CA3012693C
(en)
|
2016-02-04 |
2022-08-23 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals having an engineered angptl8 gene
|
|
JP6765433B2
(ja)
|
2016-02-12 |
2020-10-07 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
異常な核型の検出のための方法
|
|
AU2017221425A1
(en)
|
2016-02-16 |
2018-08-23 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals having a mutant kynureninase gene
|
|
CN109068621B
(zh)
|
2016-02-29 |
2021-07-20 |
再生元制药公司 |
具有人源化的tmprss基因的啮齿类动物
|
|
EP3437001A1
(en)
|
2016-03-29 |
2019-02-06 |
Regeneron Pharmaceuticals, Inc. |
Genetic variant-phenotype analysis system and methods of use
|
|
AU2017268458B2
(en)
|
2016-05-20 |
2022-07-21 |
Regeneron Pharmaceuticals, Inc. |
Methods for breaking immunological tolerance using multiple guide RNAS
|
|
EP3462853B1
(en)
|
2016-06-03 |
2023-03-01 |
Regeneron Pharmaceuticals, Inc. |
Rodents expressing exogenous terminal deoxynucleotidyltransferase
|
|
KR20240113990A
(ko)
|
2016-06-27 |
2024-07-23 |
더 리젠츠 오브 더 유니버시티 오브 캘리포니아 |
암 치료 조합
|
|
WO2018001241A1
(zh)
|
2016-06-28 |
2018-01-04 |
北京百奥赛图基因生物技术有限公司 |
一种pd-1基因修饰人源化动物模型的构建方法及其应用
|
|
CN109803530A
(zh)
|
2016-07-29 |
2019-05-24 |
瑞泽恩制药公司 |
包含引起c-截短的原纤维蛋白-1表达的突变的小鼠
|
|
KR102294755B1
(ko)
|
2016-09-30 |
2021-08-31 |
리제너론 파마슈티칼스 인코포레이티드 |
C9orf72 유전자좌에서 헥사뉴클레오티드 반복 확장을 갖는 비인간 동물
|
|
PL3766343T3
(pl)
|
2016-11-04 |
2022-09-26 |
Regeneron Pharmaceuticals, Inc. |
Zwierzęta inne niż człowiek posiadające zmodyfikowany sposobami inżynierii locus łańcucha lekkiego lambda immunoglobuliny
|
|
CN110662421B
(zh)
|
2017-01-19 |
2023-03-24 |
欧莫诺艾比公司 |
来自具有多个重链免疫球蛋白基因座的转基因啮齿类动物的人抗体
|
|
AU2018224227A1
(en)
|
2017-02-27 |
2019-08-29 |
Regeneron Pharmaceuticals, Inc. |
Non-human animal models of Retinoschisis
|
|
ES3033963T3
(en)
|
2017-07-31 |
2025-08-11 |
Regeneron Pharma |
Method of testing the ability of a crispr/cas9 nuclease to modify a target genomic locus in vivo, by making use of a cas-transgenic mouse or rat which comprises a cas9 expression cassette in its genome
|
|
US11021719B2
(en)
|
2017-07-31 |
2021-06-01 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for assessing CRISPER/Cas-mediated disruption or excision and CRISPR/Cas-induced recombination with an exogenous donor nucleic acid in vivo
|
|
KR102696334B1
(ko)
|
2017-09-29 |
2024-08-21 |
리제너론 파마슈티칼스 인코포레이티드 |
인간화 C1q 복합체를 발현하는 비인간 동물
|
|
WO2019067875A1
(en)
|
2017-09-29 |
2019-04-04 |
Regeneron Pharmaceuticals, Inc. |
NON-HUMAN ANIMALS COMPRISING A HUMANIZED TTR LOCUS AND METHODS OF USE
|
|
WO2019072241A1
(en)
|
2017-10-13 |
2019-04-18 |
Beijing Biocytogen Co., Ltd |
NON-HUMAN ANIMAL GENETICALLY MODIFIED WITH PD-1 HUMAN OR CHIMERIC
|
|
CN109666701B
(zh)
*
|
2017-10-13 |
2021-08-24 |
百奥赛图(北京)医药科技股份有限公司 |
一种pd-1基因修饰人源化动物模型的构建方法及其应用
|
|
AU2018375796B2
(en)
|
2017-11-30 |
2024-11-21 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals comprising a humanized TRKB locus
|
|
PT3720279T
(pt)
|
2017-12-05 |
2022-10-06 |
Regeneron Pharma |
Ratinhos tendo uma cadeia leve lambda de imunoglobulina manipulada e seus usos
|
|
WO2019183123A1
(en)
|
2018-03-19 |
2019-09-26 |
Regeneron Pharmaceuticals, Inc. |
Transcription modulation in animals using crispr/cas systems
|
|
AU2019242586B2
(en)
|
2018-03-26 |
2025-09-11 |
Regeneron Pharmaceuticals, Inc. |
Humanized rodents for testing therapeutic agents
|
|
HRP20250986T1
(hr)
|
2018-04-06 |
2025-10-24 |
Regeneron Pharmaceuticals, Inc. |
Antitijelo agonista leptinskog receptora za upotrebu u povećanju koštane mase kod osobe koja pati od metaboličke disfunkcije ili hipoleptinemije
|
|
JP2021525927A
(ja)
|
2018-06-01 |
2021-09-27 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
スパースベクトルベースのマトリクス変換のための方法およびシステム
|
|
IL318469A
(en)
|
2018-06-14 |
2025-03-01 |
Regeneron Pharma |
Non-human animals capable of reorganizing transgenic DH-DH, and their uses
|
|
PL3823443T3
(pl)
|
2018-07-16 |
2024-09-23 |
Regeneron Pharmaceuticals, Inc. |
Modele gryzoni z chorobą ditra i ich zastosowania
|
|
CN109504708A
(zh)
*
|
2018-12-03 |
2019-03-22 |
江苏集萃药康生物科技有限公司 |
一种筛选标记自我删除的基因打靶载体及方法
|
|
CN113423831B
(zh)
|
2018-12-20 |
2023-03-10 |
瑞泽恩制药公司 |
核酸酶介导的重复扩增
|
|
WO2020152607A1
(en)
|
2019-01-22 |
2020-07-30 |
St. Jude Children's Research Hospital |
Modulation of lc3-associated endocytosis pathway and genetically modified non-human animals as a model of neuroinflammation and neurodegeneration
|
|
EP3927832A4
(en)
*
|
2019-02-18 |
2022-11-30 |
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. |
GENETICALLY MODIFIED NON-HUMAN ANIMALS WITH HUMANIZED IMMUNOGLOBULIN LOCUS
|
|
AU2020226865A1
(en)
|
2019-02-22 |
2021-07-29 |
Regeneron Pharmaceuticals, Inc. |
Rodents having genetically modified sodium channels and methods of use thereof
|
|
IL286905B2
(en)
|
2019-04-04 |
2024-06-01 |
Regeneron Pharma |
Non-human animals containing the human coagulation factor 12 locus
|
|
CN113795588B
(zh)
|
2019-04-04 |
2025-02-25 |
瑞泽恩制药公司 |
用于在靶向性载体中无瘢痕引入靶向修饰的方法
|
|
US11136353B2
(en)
|
2019-04-15 |
2021-10-05 |
Qwixel Therapeutics Llc |
Fusion protein composition(s) comprising masked type I interferons (IFNA and IFNB) for use in the treatment of cancer and methods thereof
|
|
WO2020247452A1
(en)
|
2019-06-04 |
2020-12-10 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals comprising a humanized ttr locus with a beta-slip mutation and methods of use
|
|
CA3136478A1
(en)
|
2019-06-05 |
2020-12-10 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals having a limited lambda light chain repertoire expressed from the kappa locus and uses thereof
|
|
SG11202111256XA
(en)
|
2019-06-07 |
2021-11-29 |
Regeneron Pharma |
Non-human animals comprising a humanized albumin locus
|
|
WO2020264339A1
(en)
|
2019-06-27 |
2020-12-30 |
Regeneron Pharmaceuticals, Inc. |
Modeling tdp-43 proteinopathy
|
|
CN114423785B
(zh)
|
2019-07-01 |
2025-04-22 |
通尼克斯制药有限公司 |
抗-cd154抗体及其用途
|
|
US20240058466A1
(en)
|
2019-10-04 |
2024-02-22 |
TAE Life Sciences |
Antibody Compositions Comprising Fc Mutations and Site-Specific Conjugation Properties For Use In Treating Cancer, Immunological Disorders, and Methods Thereof
|
|
WO2021108363A1
(en)
|
2019-11-25 |
2021-06-03 |
Regeneron Pharmaceuticals, Inc. |
Crispr/cas-mediated upregulation of humanized ttr allele
|
|
US12250931B2
(en)
|
2020-01-28 |
2025-03-18 |
Regeneron Pharmaceuticals, Inc. |
Genetically modified mouse with a humanized PNPLA3 gene and methods of use
|
|
US20230081547A1
(en)
|
2020-02-07 |
2023-03-16 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals comprising a humanized klkb1 locus and methods of use
|
|
EP4125348A1
(en)
|
2020-03-23 |
2023-02-08 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals comprising a humanized ttr locus comprising a v30m mutation and methods of use
|
|
EP4138550A1
(en)
|
2020-04-21 |
2023-03-01 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals having a humanized cxcl13 gene
|
|
CN115667532A
(zh)
|
2020-06-02 |
2023-01-31 |
百奥赛图(北京)医药科技股份有限公司 |
具有共有轻链免疫球蛋白基因座的经遗传修饰的非人动物
|
|
RU2751237C1
(ru)
*
|
2020-06-10 |
2021-07-12 |
Регенерон Фармасьютикалс, Инк. |
Способы и композиции для направленной модификации генома
|
|
JP2023541216A
(ja)
|
2020-06-25 |
2023-09-29 |
ヒューマブ カンパニー リミテッド |
ヘテロ接合型トランスジェニック動物
|
|
IL301137A
(en)
|
2020-09-11 |
2023-05-01 |
Regeneron Pharma |
Identification and production of antigen-specific antibodies
|
|
US12082566B2
(en)
|
2020-10-01 |
2024-09-10 |
Regeneron Pharmaceuticals, Inc. |
Rodent animals expressing human CR1
|
|
US12012441B2
(en)
|
2020-10-26 |
2024-06-18 |
Neptune Biosciences Llc |
Engineered human IL-21 cytokines and methods for using the same
|
|
CN116848254A
(zh)
|
2020-12-16 |
2023-10-03 |
瑞泽恩制药公司 |
表达人源化Fcα受体的小鼠
|
|
WO2022140221A1
(en)
|
2020-12-21 |
2022-06-30 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals having a humanized tslp gene, a humanized tslp receptor gene, and/or a humanized il7ra gene
|
|
EP4559939A3
(en)
|
2020-12-23 |
2025-09-24 |
Regeneron Pharmaceuticals, Inc. |
Nucleic acids encoding anchor modified antibodies and uses therof
|
|
AU2022205313A1
(en)
|
2021-01-06 |
2023-07-20 |
Tonix Pharma Limited |
Methods of inducing immune tolerance with modified anti-cd154 antibodies
|
|
AU2022249328A1
(en)
|
2021-03-31 |
2023-09-21 |
Regeneron Pharmaceuticals, Inc. |
Genetically modified mice comprising humanized cellular immune system components with improved diversity of tcrβ repertoire
|
|
US20240199725A1
(en)
|
2021-04-16 |
2024-06-20 |
Korea University Research And Business Foundation |
Human antibody targeting covid-19 virus
|
|
CA3221878A1
(en)
|
2021-06-18 |
2022-12-22 |
David Stover |
Fusion protein composition(s) comprising masked type i interferons (ifna and ifnb) for use in the treatment of cancer and methods thereof
|
|
EP4423271A2
(en)
|
2021-10-28 |
2024-09-04 |
Regeneron Pharmaceuticals, Inc. |
Crispr/cas-related methods and compositions for knocking out c5
|
|
IL312971A
(en)
|
2021-12-08 |
2024-07-01 |
Regeneron Pharma |
Mutant myocilin disease model and uses thereof
|
|
WO2023122506A1
(en)
|
2021-12-20 |
2023-06-29 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals comprising humanized ace2 and tmprss loci
|
|
EP4475671A1
(en)
|
2022-02-07 |
2024-12-18 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for defining optimal treatment timeframes in lysosomal disease
|
|
KR20240144138A
(ko)
|
2022-02-11 |
2024-10-02 |
리제너론 파마슈티칼스 인코포레이티드 |
4r 타우 표적화제를 스크리닝하기 위한 조성물 및 방법
|
|
WO2023212560A1
(en)
|
2022-04-26 |
2023-11-02 |
Regeneron Pharmaceuticals, Inc. |
A rodent model of fibrodysplasia ossificans progressiva
|
|
EP4531554A1
(en)
|
2022-05-31 |
2025-04-09 |
Regeneron Pharmaceuticals, Inc. |
Animal model of tdp-43 proteinopathy
|
|
WO2023235725A2
(en)
|
2022-05-31 |
2023-12-07 |
Regeneron Pharmaceuticals, Inc. |
Crispr-based therapeutics for c9orf72 repeat expansion disease
|
|
US20230417899A1
(en)
|
2022-06-27 |
2023-12-28 |
Oshkosh Corporation |
Position tracking for a lift device
|
|
CA3260622A1
(en)
|
2022-07-19 |
2024-01-25 |
Regeneron Pharmaceuticals, Inc. |
GENETICALLY MODIFIED ANIMAL MODEL AND ITS USE TO MODEL THE HUMAN IMMUNE SYSTEM
|
|
KR20250077529A
(ko)
|
2022-09-22 |
2025-05-30 |
리제너론 파아마슈티컬스, 인크. |
인간 세포 면역계의 성분을 발현하는, 유전자적으로 변형된 마우스
|
|
US20240224964A9
(en)
|
2022-09-29 |
2024-07-11 |
Regeneron Pharmaceuticals, Inc. |
Correction of hepatosteatosis in humanized liver animals through restoration of il6/il6r/gp130 signaling in human hepatocytes
|
|
CN120603491A
(zh)
|
2023-02-01 |
2025-09-05 |
瑞泽恩制药公司 |
包含修饰的klhdc7b基因座的动物
|
|
WO2024258743A1
(en)
|
2023-06-13 |
2024-12-19 |
Adcentrx Therapeutics, Inc. |
Methods and compositions related to antibodies and antibody drug conjugates (adcs) that bind nectin-4 proteins
|
|
US20240415103A1
(en)
|
2023-06-16 |
2024-12-19 |
Regeneron Pharmaceuticals, Inc. |
Vectors, genetically modified cells, and genetically modified non-human animals comprising the same
|
|
WO2025122669A1
(en)
|
2023-12-05 |
2025-06-12 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals having a humanized complement factor b gene
|
|
US20250255282A1
(en)
|
2024-02-08 |
2025-08-14 |
Regeneron Pharmaceuticals, Inc. |
Vectors, genetically modified cells, and genetically modified non-human animals comprising the same
|
|
WO2025212991A1
(en)
|
2024-04-05 |
2025-10-09 |
Regeneron Pharmaceuticals, Inc. |
Rodent models of disease
|
|
WO2025235388A1
(en)
|
2024-05-06 |
2025-11-13 |
Regeneron Pharmaceuticals, Inc. |
Transgene genomic identification by nuclease-mediated long read sequencing
|
|
WO2025250495A1
(en)
|
2024-05-28 |
2025-12-04 |
Regeneron Pharmaceuticals, Inc. |
Acceleration of human hepatocyte engraftment in humanized liver animals by supplementing paracrine ligands or agonists that activate human liver regeneration signals
|